Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen Idec 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Biogen Idec 2Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec

2Q Revenues: $773 million (+17%)

2Q Earnings: $186 million (net loss of $171 million in 2Q2006)

YTD Revenues: $1.5 billion (+17%)

YTD Earnings: $318 million (net loss of $48 million in 2Q2006)

Comments: Avonex sales rose 8% to $462 million, Rituxan was up 12% to $231 million and Tysabri brought in $48 million in sales to BI ($72 million in total sales, with the remainder going to partner Elan). The company announced that there are 14,000 MS patients using Tysabri.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters